| ￥3300 | |
| Z06309-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | >?95%?as?determined?by?Bis?Tris?PAGE? | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 45.7 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-55 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in PBS, 10% Glycerol (pH 8.0). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Innate immunity protein Tag7 (PGRP-S, PGLYRP1) can interact with the TNFα receptor, TNFR1, and block the transduction of apoptotic signals through this receptor. A complex formed between the Tag7 protein and the major heat shock protein Hsp70 can activate TNFR1 receptor and induce tumor cell death via either apoptotic or necroptotic pathway. |
| Synonyms | PGRP-S; PGLYRP1; PGLYRP; PGRP; TNFSF3L; PGRP-SMGC126894; PGRPSMGC126896; TAG7; Tasg7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
